Amyloid-beta targeted therapeutic approaches for Alzheimer's disease: long road ahead

Curr Drug Targets. 2022 Apr 21. doi: 10.2174/1389450123666220421124030. Online ahead of print.ABSTRACTAlzheimer's disease (AD) is a progressive neurodegenerative disorder which is characterized by memory impairment and cognitive decline. The obvious pathological features of AD are still amyloid plaques and neurofibrillary tangles. Development of disease-modifying treatments for AD has been challenging, with almost all drugs aborted. The failures of several amyloid-targeting candidates have caused the amyloid cascade hypothesis has been distrusted. Despite this, targeting amyloid-β (Aβ) active immunotherapy provided some positive results to support this hypothesis and clinical trials of these candidates are ongoing. In this review, we describe the latest advance in therapeutic strategies based on amyloidogenic processing and evaluate the pros and cons of each treatment strategy. We also highlight the current status of the hottest immunotherapy and discuss the future development direction.PMID:35593357 | DOI:10.2174/1389450123666220421124030
Source: Current Drug Targets - Category: Drugs & Pharmacology Authors: Source Type: research